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ABSTRACT
Both Fanconi anemia (FA) and telomere dysfunction
are associated with chromosome instability and an
increased risk of cancer. Because of these similari-
ties, we have investigated whether there is a rela-
tionship between the FA protein, FANCD2 and
telomeres. We find that FANCD2 nuclear foci colo-
calize with telomeres and PML bodies in immorta-
lized telomerase-negative cells. These cells
maintain telomeres by alternative lengthening of tel-
omeres (ALT). In contrast, FANCD2 does not colo-
calize with telomeres or PML bodies in cells which
express telomerase. Using a siRNA approach we
find that FANCA and FANCL, which are components
of the FA nuclear core complex, regulate FANCD2
monoubiquitination and the telomeric localization of
FANCD2 in ALT cells. Transient depletion of
FANCD2, or FANCA, results in a dramatic loss of
detectable telomeres in ALT cells but not in telomer-
ase-expressing cells. Furthermore, telomere loss
following depletion of these proteins in ALT cells
is associated with decreased homologous recombi-
nation between telomeres (T-SCE). Thus, the FA
pathway has a novel function in ALT telomere main-
tenance related to DNA repair. ALT telomere main-
tenance is therefore one mechanism by which
monoubiquitinated FANCD2 may promote genetic
stability.
INTRODUCTION
Fanconi anemia (FA) is a multigenic disease associated
with bone marrow failure and cancer susceptibility, par-
ticularly acute myelogenous leukemia (AML) and
squamous cell carcinoma of the head and neck (1,2). FA
cells display chromosome fragility, characterized by chro-
mosome breakage and the formation of radial chromo-
somes, in response to DNA interstrand crosslinkers such
as mitomycin C (MMC). FA cells are also hypersensitive
to MMC (2–4). Together, these results suggest that
Fanconi anemia is linked to a defect in the cellular
response to DNA damage. Importantly, the role of FA
proteins in DNA damage responses is not well
understood.
The genes for 13 FA subtypes (A, B, C, D1, D2, E, F,
G, I, J, L and M and N) have been identiﬁed (2,4,5). The
encoded FA proteins cooperate in the FA pathway (3).
Eight of the FA proteins (A, B, C, E, F, G, L and M)
assemble into a nuclear core complex that is required for
the monoubiquitination of FANCD2 and FANCI (2–4).
Monoubiquitination of FANCD2 is critical for the
normal function of DNA damage responses. A non-ubi-
quitinable mutant of FANCD2, mutated at the site of
ubiquitin conjugation, is completely incapable of restoring
MMC resistance to FANCD2-deﬁcient cells (3,6,7). In
contrast, a non-ubiquitinable mutant of FANCI partially
restores MMC resistance in FANCI-deﬁcient cells (8).
Monoubiquitination of FANCD2 is required for the
assembly of this protein into nuclear foci during an unper-
turbed S phase or in response to DNA damage (3,9).
Consistent with a role for FANCD2 in DNA damage
responses, FANCD2 foci colocalize with BRCA1 and
RAD51 foci (9). The ATR checkpoint kinase, along
with the FA nuclear core complex, is involved in the reg-
ulation of FANCD2 monoubiquitination and the assem-
bly of FANCD2 foci in response to DNA damage (10).
Telomere dysfunction can occur either through progres-
sive telomere shortening or other changes in telomere
structure that leave the chromosome ends unprotected
(11,12). Similar to FA, telomere dysfunction results in
chromosome instability, in particular chromosome end
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chromosome instability phenotype suggests that FA pro-
teins could have some role in telomere function.
While expression of telomerase is the predominant
mechanism of stabilizing telomeres in human tumor
cells, the alternative lengthening of telomeres (ALT) path-
way is utilized in about 10–15% of human tumors (13,14).
The ALT pathway maintains telomeres through homolo-
gous recombination (15,16). ALT cells display a corre-
sponding increase in sister chromatid exchanges at
telomeres (T-SCE), as compared to non-ALT cells
(17,18). Importantly, telomeres in ALT cells have a
more heterogeneous length and display increased chromo-
some instability, including breaks, fusions and fragments,
as compared to telomerase-expressing cells (19,20).
Another characteristic of human ALT cells is that pro-
myelocytic leukemia (PML) nuclear bodies (APBs for
ALT-associated PML bodies) colocalize with telomeres
during late S phase/G2 (21–23). Other proteins involved
in DNA damage responses, such as NBS1 and MRE11
(22), BRCA1 (24), BLM (23,25), RPA (26,27) and
SMC5/6 (28), also localize to APBs. Relatively little is
known, however, about how, or whether, these proteins
function at ALT telomeres.
The function of FA proteins in DNA damage responses
has been largely characterized in non-ALT cells (2). Here
we demonstrate that FANCD2 localizes to telomeres in
immortalized telomerase-negative ALT cells, but not in
immortalized/transformed lines expressing telomerase.
We ﬁnd that the localization of FANCD2 to ALT telo-
meres requires FANCA and FANCL, either with or with-
out exposure to DNA damaging agents. Furthermore, we
demonstrate that the ATR checkpoint kinase is required
for the localization of FANCD2 to telomeres after ALT
cells are exposed to MMC. Our results also demonstrate
that transient depletion of either FANCD2 or FANCA is
associated with a decrease in recombination between the
telomeres (T-SCE) and with a dramatic loss of detect-
able telomeres in ALT cells. In contrast, depletion of
FANCD2 or FANCA does not result in decreased
T-SCE or loss of detectable telomeres in telomerase-
expressing cells. Our results suggest that monoubiquiti-
nated FANCD2 has a role in the maintenance of
telomeres at chromosome ends in ALT cells that may be
related to its function in cellular responses to DNA
damage. Importantly, ALT telomeres may serve as a
model system for understanding the function of FA
proteins in homologous recombination.
MATERIALS AND METHODS
Cell culture
Transformed ALT cell lines (U2OS, GM847 and WI38/
VA13) and telomerase-expressing cell lines (HeLa, MCF7
and 293-EBNA) (26) were cultured in DMEM
(Invitrogen) supplemented with 15% fetal bovine serum
(Sigma), 100U/ml Penicillin, 100mg/ml Streptomycin and
2mM L-glutamine at 378C, 5% CO2.
DNA replication was arrested by treatment with 2mM
hydroxyurea (HU), added from a 200mM stock in growth
medium which was kept at –208C. Mitomycin C was
added from a 3mM stock in ethanol kept at –208C.
Immunofluorescence microscopy
Adherent cells were grown on 12mm diameter glass cover-
slips, coated with poly-D-lysine, for a minimum of 24h
prior to treatment or ﬁxation. For detection of ATR,
cells were ﬁxed with 3% paraformaldehyde for 10min.
Cells were then permeabilized with PBS containing 0.5%
Triton X-100 for 5min at RT. For immunolocalization of
all other antigens, cells were ﬁxed with 2% paraformalde-
hyde for 20min at RT, permeabilized and processed for
immunoﬂuorescence microscopy as we have described pre-
viously (29).
For immunolocalization of FANCD2 on mitotic chro-
mosomes, chromosome spreads were prepared. Cells were
incubated with 1mg/ml nocodazole for 3h and cells were
swollen in 0.8% sodium citrate for 5min at 378C. Spreads
were prepared by centrifugation at 1200rpm for 2min
using a Thermo Shandon Cytospin 4 apparatus. Cells
were then ﬁxed with 2% paraformaldehyde for 20min
at RT.
Primary antibodies included anti-FANCD2 (E35, 1:200,
rabbit, obtained from Dr Alan D’Andrea, Dana-Farber
Cancer Institute), anti-ATR (Ab-2, Calbiochem, 1:100,
rabbit), anti-PML (N-19 from Santa Cruz, 1:300, goat)
and anti-TRF1 (TRF-78 from Abcam, 1:100, mouse).
Secondary antibodies included FITC-conjugated donkey
anti-goat IgG, FITC-conjugated donkey anti-mouse
or anti-rabbit IgG and Rhodamine B-conjugated donkey
anti-rabbit IgG (Jackson Immunoresearch; 1:500).
Labeled cells were observed with a Zeiss Axiovert 200M
microscope and images were collected with a Hamamatsu
Camera using Openlab software (Improvision). Images
were processed into ﬁgures using Photoshop (Adobe).
Combinedimmunofluorescence microscopy and
fluorescence in situ hybridization (FISH)
To simultaneously detect FANCD2 or TRF1 with speciﬁc
antibodies, and telomeric DNA with a ﬂuorescent DNA
probe, cells were grown on glass coverslips coated with
poly-D-lysine. Cells were ﬁxed for 10min with 3% para-
formaldehyde in PBS, and then extracted with 0.5%
Triton X-100 in PBS for 5min on ice. Following a PBS
wash, cells were incubated with primary antibodies to
FANCD2 (E35) or TRF1 (TRF78) as described pre-
viously (29). Secondary antibodies were diluted 200-fold.
Cells were washed three times with PBS, post-ﬁxed with
3% paraformaldehyde in PBS for 10min at RT, and then
exposed to two 10min incubations with 70% ethanol at
 208C. Samples were air dried and hybridization mixture
(50% formamide, 10% dextran sulfate, 5X Denhardt’s
solution, 2X SSC, 0.5ng/ml yeast tRNA and 0.3mg/ml
Cy3-PNA telomeric probe [Cy3-(CCCTAA)3]) was
added. Cells were incubated at 808C for 3min and then
overnight at RT with protection from ambient light. Cells
were washed for 30min at RT with 50% formamide/2X
SSC, then twice for 5min each with 2X SSC. Finally, cells
were washed twice with PBS and were mounted in
Vectashield containing DAPI.
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Expression of targeted genes was knocked down by tran-
sient expression of siRNAs directed against ATR,
FANCA and GFP, as we have described previously (10).
SiRNAs directed against FANCD2 (30) and FANCL (31)
were also utilized. Cells were either left untreated or were
exposed to 2mM HU or 0.5mM mitomycin C for 24h.
Cells were harvested 96h post-transfection.
ShRNA and transduction
FANCA was depleted in GM847 ALT cells using a lenti-
viral shRNA. The LeGO-G vector (32) was kindly pro-
vided by Kristoﬀer Weber and Dr Boris Fehse (University
Hospital Eppendorf, Hamburg, Germany). Virus was pro-
duced by transfection of 293T cells with LeGO-G, along
with the packaging plasmids pRRE and pRSV-Rev, and
pVSV-G (32). Virus was concentrated by ultracentrifuga-
tion and then centrifuged through a 20% sucrose cushion
for additional puriﬁcation. Virus was aliquoted and stored
at –808C. Target cells were transduced 3X, at approxi-
mately 12h intervals, with virus in growth medium
containing 8mg/ml polybrene. Cells were analyzed at
96h after beginning transduction.
Immunoblotting
Cells were lysed, protein concentrations determined from
supernatants, and sample buﬀer added to combined super-
natants and pellets to prepare whole cell lysates as we
have described previously (29). Equivalent amounts
of proteins were loaded for each sample, followed by
SDS–PAGE (6% polyacrylamide, bis-acrylamide).
Proteins were transferred to nitrocellulose, blocked, and
incubated with primary antibodies as previously described
(9). Antibodies included anti-FANCA (1:1000) generously
provided by Dr Maureen Hoatlin (Oregon Health &
Sciences University, Portland, OR, USA), anti-FANCD2
(E35, 1:1000) (3), anti-FANCL (1:2000) (31) from Dr
Ruhikanta Meetei (Cincinnati Children’s Research
Foundation), anti-ATR (1:500) and anti-actin (C4,
1:2000) from Dr James Lessard (Cincinnati Children’s
Research Foundation). Membranes were washed, incu-
bated with HRP-linked secondary antibodies
(Amersham), and signals detected by chemiluminescence
(Amersham) as previously described (9).
Assayof signal-free ends byFISH
Followingtransfection withsiRNAs,U2OSandHeLacells
were exposed to 1mg/ml nocodazole for 5h. All cells were
collected and pooled following trypsinization. Cells were
swollen, ﬁxed, dried onto slides and prepared for hybridi-
zation, as described previously (33). Hybridization mix
[70% formamide, 0.06X SSC, 0.2% bovine serum albumin,
0.5ng/ml yeast tRNA (Sigma) and 0.5ng/ml Cy3-labeled
telomeric peptide nucleic acid (PNA) probe (Applied
Biosystems)] was applied and covered with a plastic
coverslip. Slides were placed on a heat block at 838C
for 3min and hybridized for 3h at RT. Coverslips were
then removed, and slides were washed twice in 70%
formamide and 0.06X SSC, pH 7.2, then twice in PBS
containing 0.05% Triton X-100. Slides were then
mounted with a coverslip using Vectashield that contained
DAPI.
Images were collected with constant settings and no
threshold signal, so that only the brightest metaphase
telomeric signals approached saturating intensity. Due to
the wide heterogeneity of telomere lengths in ALT cells
(16,19), longer exposure times were utilized to image telo-
meres in HeLa cells in a linear range. Images of meta-
phases with spread chromosomes were collected and
signal-free ends were counted from merged images.
Measurements oftelomere sister chromatidexchange
(T-SCE)
T-SCE was analyzed by chromosome orientation ﬂuores-
cence in situ hybridization (CO-FISH) as previously
described (34), with slight modiﬁcation. Brieﬂy, U2OS
or HeLa cells were grown overnight and then incubated
with 10mM bromodeoxyuridine (BrdU) for 16h, with
1mg/ml nocodazole added for the last 5h. Cells were col-
lected following trypsinization and were resuspended in
75mM KCl for 20min prior to ﬁxation and preparation
of metaphase spreads. Following incubation with Hoechst
33258, treatment with UV light (using a Stratalinker 1800
UV irradiator), and digestion with Exonuclease III
(Promega), cells were hybridized overnight with 0.5ng of
Cy3-(TTAGGG)3 telomeric probe. Slides were then
washed and mounted with a coverslip and Vectashield
containing DAPI.
Images were collected and T-SCE counts were made
from merged images. A telomere signal split between
sister chromatids at a particular end of a chromosome
was counted as a T-SCE event. In cases where both chro-
mosome ends displayed a split signal, this was counted as
two T-SCE events. To determine the number of T-SCE
events relative to the number of chromosome ends with a
detectable signal, the total number of T-SCE events was
divided by the number of chromosome ends with a detect-
able telomere signal, whether single or split.
Flow FISH
Telomere lengths in interphase cells were quantitated
by FISH with Cy3-OO-(CCCTAA)3 probe using ﬂow
cytometry, as previously described (35). Flow cytometry
was performed on a FacsCalibur instrument (Becton–
Dickinson). Aggregated cells were gated out.
RESULTS
FANCD2 colocalizes withtelomeres inALT cells
The FA protein FANCD2 forms nuclear foci during S
phase in the absence of exogenous DNA damage (9).
Whether S phase FANCD2 foci associate with speciﬁc
substructures within the nucleus is unknown. Since
another DNA damage response protein, NBS1, coloca-
lizes with telomeres in non-ALT cells (36), we tested
whether spontaneous FANCD2 foci colocalize with telo-
meres in cells which maintain telomere length by either of
two diﬀerent mechanisms: telomerase expression or ALT.
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FANCD2 foci with the telomere-binding protein TRF1
(37) (Figure 1). FANCD2 did not colocalize with TRF1
in the telomerase-expressing cell line HeLa (Figure 1A) or
in proliferating primary human ﬁbroblasts (GM00038)
(data not shown). We did ﬁnd, however, that FANCD2
colocalized with TRF1 in the ALT cell line, GM847
(Figure 1A). Telomeres aggregate (cluster) in ALT cells
(22,26,38). As a result, ALT cells frequently have a smaller
number of TRF1 foci, which are larger than those
detected in telomerase-expressing cells. We found that
FANCD2 also colocalized with the telomeric protein
TRF2 in 35.9 2.1% of GM847 ALT cells, but not in
HeLa cells (1.3 0.6%).
A quantitative analysis of three telomerase-
expressing cell lines (HeLa, MCF7 and 293-EBNA)
and three ALT cell lines (GM847, WI38 VA13/R2 and
U2OS) showed that spontaneous FANCD2 foci formed
in each of the cell lines (Figure 1B). FANCD2 foci specif-
ically colocalized with TRF1at telomeres in each of the
ALT cell lines (34.8 2.6%, 15.9 1.7% and 12.4 1.3%
of randomly cycling GM847, WI38 VA13/R2 and U2OS
cells, respectively), but not in any of the telomerase-
expressing cell lines which were tested (less than 2% of
randomly cycling HeLa, MCF7 or 293-EBNA cells)
(Figure 1B).
We examined whether colocalization of FANCD2 with
TRF1 is cell-cycle regulated. For these experiments, ALT
(U2OS) cells were synchronized using a double thymidine
treatment. Just prior to release from synchronization (0h),
U2OS cells were at the G1-S boundary (Figure 2A). Cells
were in mid-S phase at 6h after release and in G2-mitosis
by 12h of release from synchronization. At 15h after
release from synchronization, an accumulation of cells
with a 2N DNA content was evident, indicating passage
through mitosis and return to G1.
Nearly all U2OS cells had FANCD2 foci prior to
release from double-thymidine synchronization (0h)
(Figure 2B). The percentage of cells with FANCD2 foci
was relatively constant until it began to decline at 12h
following release from synchronization. The percentage
of cells with FANCD2 foci declined further as cells
divided and returned to G1at 15h of release.
In contrast, the colocalization of FANCD2 foci with
telomeres (TRF1) in ALT cells was low in early S phase
(0 and 3h following release from synchronization).
Colocalization of FANCD2 foci with TRF1 foci peaked
dramatically in late S/G2/mitosis at 9–12h following
release from synchronization, and decreased at 15h fol-
lowing release from synchronization when many cells had
re-entered G1 (Figure 2C). We assayed for the localization
of FANCD2 to spread mitotic chromosomes to determine
whether FANCD2 colocalizes with ALT bodies during
mitosis (Figure 2D). FANCD2 foci did not associate
with mitotic chromosomes. We conclude that colocaliza-
tion of FANCD2 foci with TRF1 foci in ALT cells is
restricted to late S phase/G2, thus explaining why coloca-
lization is not observed in every ALT cell that displays
spontaneous FANCD2 foci.
As an alternative measure of the colocalization of
FANCD2 foci with telomeres in ALT cells, we labeled
cells with FANCD2 antibodies and detected telomeric
repeat DNA by simultaneous FISH (37,39). We found
that FANCD2 foci colocalized with telomeric DNA in
two diﬀerent ALT cell lines, GM847 and U2OS
(Figure 3A). In contrast, FANCD2 foci did not colocalize
with telomeric DNA in telomerase-expressing HeLa cells
(data not shown). Furthermore, TRF1 uniformly coloca-
lized with telomeric DNA in interphase GM847 cells
(Figure 3B), and in HeLa cells (data not shown), validat-
ing the use of TRF1 antibody in subsequent ﬁgures for the
identiﬁcation of telomeres by immunoﬂuorescence micros-
copy. Consistent with a recent report (40), we also found
that TRF1 strongly colocalized with telomeric DNA fol-
lowing the induction of DNA damage (data not shown).
The promyelocytic leukemia protein (PML) forms
ALT-associated PML bodies (APBs) (21,22,26), which
also contain telomeric DNA, telomere-binding proteins,
and certain DNA repair proteins. To better understand
the behavior of FANCD2 in ALT cells, we sought to
Figure 1. FANCD2 colocalizes with the telomere-binding protein TRF1 in ALT cells. (A) Images of FANCD2 foci (red) and TRF1 foci (green) in
the telomerase-expressing line, HeLa, and in the ALT cell line, GM847. The position of the nucleus is shown by counterstaining with DAPI. (B)
Quantiﬁcation of the colocalization of FANCD2 foci with TRF1 foci. The percentage of three telomerase-expressing cell lines (HeLa, MCF7 and
293-EBNA) and three ALT cell lines (GM847, WI38/VA13 and U2OS) with ﬁve or more FANCD2 foci, or with two or more FANCD2 foci which
colocalized with the telomeric protein TRF1, is shown. Two foci were used as the standard for colocalization, since telomeres can aggregate in ALT
cells into a small number of bright telomeric foci (22,26,38). Each bar represents the average of three counts of at least 150 cells each  SD. The levels
of colocalization of FANCD2 with TRF1 in ALT cells were statistically diﬀerent from those seen in telomerase-expressing cells (P<0.01).
Nucleic Acids Research,2009, Vol.37, No. 6 1743determine whether FANCD2 colocalizes with APBs.
FANCD2 foci colocalized with PML in the ALT cell
line GM847, but did not colocalize with PML bodies in
HeLa cells (Figure 4A).
A comparison of three telomerase-expressing cell lines
(HeLa, MCF7 and 293-EBNA) and three ALT cell lines
(GM847, WI38 VA13/R2 and U2OS) shows that nearly
all cells had PML foci, regardless of the mechanism of
telomere maintenance (Figure 4B). FANCD2 colocalized
with PML in each of the ALT cell lines (15.3 1.1%,
10.9 0.9% and 3.6 0.6% of randomly cycling
GM847, WI38 VA13/R2 and U2OS cells, respectively),
but in none of the three telomerase-expressing cell lines
tested (less than 1% of randomly cycling populations of
HeLa, MCF7 or 293-EBNA cells) (Figure 4B).
Because FANCD2 preferentially colocalizes with
TRF1at late S phase/G2 (Figure 2), and because PML
also colocalizes with telomeres late in the cell cycle
(21–23), we sought to determine whether FANCD2 colo-
calizes with PML bodies in a cell-cycle-dependent manner
in ALT cells. For this purpose, we synchronized GM847
cells using a double thymidine treatment (Supplementary
Figure 1). GM847 cells were utilized for these experiments
due to the relatively high level of colocalization of
FANCD2 and PML bodies in asynchronous populations
of this ALT cell line (Figure 4B). Synchronization of
GM847 cells was similar to results obtained for U2OS
cells in Figure 2A. GM847 cells had a 2N DNA content,
consistent with synchronization at the G1/S boundary,
prior to release from the second thymidine treatment
(Supplementary Figure 1). In contrast, cells displayed a
4N DNA content, indicating the accumulation of
GM847 ALT cells at G2-M, at 12h following release
from the second thymidine treatment.
While over 85% of GM847 cells displayed FANCD2
foci at both timepoints, only 10.80 2.11% of cells
showed colocalization of FANCD2 and PML foci prior
to release from synchronization (Figure 4C). In compar-
ison, over 50% of GM847 ALT cells displayed colocaliza-
tion of FANCD2 and PML foci at G2-M 12h following
Figure 2. FANCD2 colocalizes with TRF1 foci in ALT cells in a cell-
cycle-speciﬁc manner. (A) Cell-cycle distributions of asynchronous
U2OS ALT cells, or at various timepoints following double-thymidine
synchronization, were determined by ﬂow cytometric measurements of
DNA content. (B and C) The percentage of cells with ﬁve or more
FANCD2 foci (B), or with two or more FANCD2 foci colocalized
with TRF1 foci (C), in asynchronous populations or at timepoints fol-
lowing release from double-thymidine synchronization. Each bar repre-
sents the average of three counts of 150 or more cells  SD. (D)A
representative ﬁeld of GM847 ALT cells, treated with 1mg/ml nocoda-
zole for 5h to arrest mitotic progression, contains an interphase cell
and a cell with mitotic chromosomes detected by counterstaining with
DAPI (blue). FANCD2 foci (red) were detected with E35 antibody.
Figure 3. FANCD2 colocalizes with telomeric DNA repeats in ALT
cells. (A) FANCD2 was detected with antibodies (green) and telomeric
DNA was detected with a Cy3-PNA probe (red) in the ALT cell lines
GM847 and U2OS. (B) TRF1 was detected with anti-TRF1 antibodies
(green) and telomeric DNA (red) was detected with a Cy3-PNA probe
in GM847 cells.
1744 Nucleic Acids Research, 2009, Vol. 37,No. 6release from the second thymidine treatment. Over 99% of
cells had PML bodies at either timepoint. Thus FANCD2
colocalizes with PML bodies and with TRF1 foci at the
same stages of the cell cycle.
FANCA,FANCLandATRarerequiredforthecolocalization
of FANCD2foci with TRF1foci in ALT cells
Since monoubiquitination is required for the assembly of
FANCD2 foci in telomerase-expressing cells during S
phase and in response to DNA damage (3,9), we sought
to determine whether monoubiquitination is required for
the colocalization of FANCD2 foci with TRF1 foci in
ALT cells. For this purpose, we depleted FANCA,
which is a component of the FA nuclear core complex
that is required for FANCD2 monoubiquitination
(3,10), using a siRNA that we have described previously
(10). Depletion of FANCA in ALT cells (U2OS) inhibited
FANCD2 monoubiquitination, but did not deplete
FANCD2, both in randomly cycling cells and following
exposure to HU (Figure 5A). SiRNAs directed against
FANCA also strongly inhibited FANCD2 monoubiquiti-
nation in HeLa telomerase-expressing cells (data not
shown).
The percentage of U2OS cells transfected with siGFP
that contained ﬁve or more FANCD2 foci increased
following treatment with MMC (Figure 5B). Thus, the
assembly of FANCD2 foci is induced by DNA damage
both in telomerase-expressing cells (10) and in ALT cells.
A smaller number of U2OS ALT cells with FANCD2 foci
was observed following depletion of FANCA, as com-
pared to control cells transfected with GFP siRNA. This
was true for cells grown either with or without exposure to
MMC for 24h (Figure 5B).
The colocalization of FANCD2 foci and TRF1 foci in
U2OS ALT cells is quantiﬁed in Figure 5B. Importantly,
treatment with MMC induced a strong increase in the
colocalization of FANCD2 with TRF1 foci in cells trans-
fected with a control siRNA directed against GFP
(Figure 5B). Thus, the association of FANCD2 foci
with telomeres in ALT cells may be related to a DNA
damage response at this site.
While depletion of FANCA had no eﬀect on TRF1 foci
(data not shown), it inhibited colocalization of FANCD2
and TRF1 foci, both in untreated populations of U2OS
ALT cells and following treatment with MMC for 24h. In
particular, the percentage of cells which displayed coloca-
lization of FANCD2 and TRF1 foci following treatment
with MMC was 44.3 1.3% and 15.7 1.1% in cells
transfected with siGFP and siFANCA, respectively
(Figure 5B). In contrast, while FANCA protein levels
were suppressed in HeLa cells by the siRNA directed
against FANCA, less than 2% of HeLa cells had
FANCD2 foci colocalized with TRF1 foci, either with
or without FANCA depletion (data not shown).
Next we sought to determine whether FANCA is
required for the cell-cycle-dependent colocalization of
Figure 4. FANCD2 colocalizes with PML in ALT bodies. (A) FANCD2 foci (red) and PML bodies (green) were detected in GM847 (ALT cell line)
and in HeLa cells (telomerase-expressing cell line). (B) Quantiﬁcation of the assembly of PML bodies and their colocalization with FANCD2 foci in
various telomerase-expressing cell lines and ALT cell lines. The percentage of cells with ﬁve or more PML foci, or in which two or more FANCD2
foci colocalized with PML, is shown for each cell line. The levels of colocalization of FANCD2 foci with PML foci in ALT cells were statistically
diﬀerent from those observed in telomerase-expressing cells (P<0.01). (C) The percentage of GM847 ALT cells with ﬁve or more FANCD2 foci, ﬁve
or more PML foci, or with two or more colocalized FANCD2 and PML foci at 0 or 12h following release from double-thymidine synchronization is
shown. The levels of FANCD2 colocalization with PML foci at 0 and 12h of release were statistically diﬀerent (P<0.01). Each bar represents the
average of three counts of at least 150 cells each  SD (B and C).
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were transfected with a control siRNA that targeted GFP
or with a siRNA directed against FANCA. Cells were
then synchronized in early G1 using a double thymidine
treatment, as demonstrated in Figure 2A. The colocaliza-
tion of FANCD2 foci with TRF1 foci was dramatically
increased in cells at late S/G2at 9h following release from
synchronization, as compared to cells in early G1 that had
not been released from synchronization (Figure 5C).
Critically, depletion of FANCA strongly inhibited the
colocalization of FANCD2 with the telomeric marker,
TRF1, in cells during late S phase/G2 of the cell cycle
(Figure 5C). At 9h release from synchronization, the per-
centage of cells that displayed colocalization of FANCD2
and TRF1 foci was 28.7 1.7% and 10.7 1.1% of cells
transfected with siGFP and siFANCA, respectively.
To conﬁrm the requirement for FANCD2 to be mono-
ubiquitinated in order to colocalize with telomeres, we
tested the role of another component of the FA nuclear
core complex, FANCL (Figure 5). Importantly, FANCL
is the apparent E3 ubiquitin ligase for FANCD2 (31). For
this purpose, we depleted FANCL using a siRNA that has
been described previously (31). Depletion of FANCL in
ALT cells (U2OS) inhibited FANCD2 monoubiquitina-
tion, both in randomly cycling cells and following
exposure to HU (Figure 5A). Furthermore, depletion
of FANCL in U2OS ALT cells inhibited the assembly
of FANCD2 foci either with or without exposure to
MMC (Figure 5B). Depletion of FANCL also resulted
in inhibition of the colocalization of FANCD2 foci with
TRF1 foci in U2OS ALT cells, both in untreated popula-
tions and following treatment with MMC for 24h
(Figure 5B). The percentage of cells that displayed
colocalization of FANCD2 foci with TRF1 foci in
MMC-treated U2OS ALT cells was 44.3 1.3% and
13.8 1.4% following transfection with siRNAs directed
against GFP and FANCL, respectively.
We also determined that FANCL, like FANCA, is sim-
ilarly required for cell-cycle-dependent colocalization of
FANCD2 with TRF1 foci (Figure 5C). Depletion of
FANCL inhibited the colocalization of FANCD2 foci
with TRF1 in cells synchronized in early S phase (0h
Rel.) and at late S phase/G2 (9h Rel.). In particular, the
percentage of cells that displayed colocalization of
FANCD2 foci with TRF1 foci at 9h after release from
synchronization was 28.7 1.7% and 9.2 1.2% in cells
Figure 5. FANCA and FANCL are required for the colocalization of FANCD2 foci with TRF1 foci in ALT cells. (A) U2OS (ALT) cells were
transfected with siRNAs directed against either FANCA or FANCD2, or with a control siRNA directed against GFP. In an independent experi-
ment, U2OS (ALT) cells were transfected with siRNAs directed against FANCL or GFP. Depletion of FANCA or FANCD2 (left panel), or
FANCL (right panel) was assayed on immunoblots. Cells were left untreated or were exposed to HU for 24h. The ratio of monoubiquitinated (-L) to
non-ubiquitinated (-S) FANCD2 is indicated (L/S ratio). Due to the low levels of FANCD2 protein present following transfection with the siRNA
directed against FANCD2 (siFANCD2), it was not possible to accurately measure the L/S ratio for these cells and this value was not determined
(N.D.). Antibodies directed against FANCA also recognized a non-speciﬁc band (N.S.). Immunoblots for actin are shown as a loading control. (B)
Quantiﬁcation of the percentage of U2OS cells, transfected with siRNAs directed against GFP, FANCA or FANCL, which had ﬁve or more
FANCD2 foci in untreated populations or following exposure to 0.5mM MMC for 24h (left). Quantiﬁcation of the percentage of U2OS cells,
transfected with siRNAs directed against GFP, FANCA, or FANCA, which had two or more FANCD2 foci colocalized with TRF1 foci is also
shown (right panel in ﬁgure part). Cells were left untreated or were exposed to 0.5mM MMC for 24h. (C) Quantiﬁcation of the percentage of U2OS
cells, transfected with siRNAs directed against GFP, FANCA or FANCL, which had two or more FANCD2 foci colocalized with TRF1 foci, at 0 or
9h following release from double-thymidine synchronization. Each bar represents the average of three counts of 150 or more cells  SD, except that
three counts from two experiments were included for cells transfected with siGFP. The behavior of FANCD2 foci was statistically diﬀerent in cells
transfected with siFANCA or siFANCL, as compared to controls transfected with siGFP (P<0.01) (B and C).
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that depletion of FANCA or FANCL similarly inhibits
FANCD2 monoubiquitination and the colocalization of
FANCD2 with TRF1 foci, we conclude that monoubiqui-
tination of FANCD2 is required for its assembly into
ALT-associated PML bodies.
The assembly of FANCD2 foci in response to DNA
damage or replication stress is regulated by the ATR
checkpoint kinase in telomerase-expressing cells (10).
Depletion of ATR in U2OS ALT cells using a siRNA
we have described previously (10), inhibited FANCD2
monoubiquitination in HU-treated cells (Figure 6A). But
depletion of ATR did not inhibit FANCD2 monoubiqui-
tination in untreated cells. Quantiﬁcation shows that
depletion of ATR resulted in a decrease in the percentage
of cells treated with MMC that had FANCD2 foci
(Figure 6B) and in the percentage of cells in which
FANCD2 foci colocalized with TRF1 foci (Figure 6C).
In cells treated with MMC, 45.5 1.4 and 6.3 1.7% of
U2OS cells transfected with siGFP and siATR, respec-
tively, displayed colocalization of FANCD2 and TRF1
foci. But depletion of ATR did not alter the number of
TRF1 foci (data not shown). Thus, the DNA damage-
induced assembly of FANCD2 foci at telomeres in ALT
cells requires ATR.
To better understand how ATR regulates the colocali-
zation of FANCD2 foci with TRF1 in ALT cells, we
sought to determine whether ATR colocalizes with
TRF1 foci in such cells (Figure 6D). As determined by
immunoﬂuorescence microscopy, ATR foci colocalized
with TRF1 foci in untreated GM847 ALT cells
(Figure 6D). ATR also colocalized with TRF1 foci in
GM847 cells following treatment with MMC, but did
not colocalize with TRF1 in telomerase-expressing HeLa
cells (data not shown). Thus, ATR may regulate the
monoubiquitination of FANCD2 at ALT telomeres by
localizing to ALT-associated PML bodies.
Depletion ofFANCA or FANCD2 results inloss of
telomere signals at chromosome endsin ALT cells
To determine whether FANCD2 has a function at telo-
meres in ALT cells, we performed FISH of metaphase
spreads using a Cy3-labeled telomeric peptide-nucleic
acid (PNA) probe. As examples, representative images
are shown for U2OS (ALT) and HeLa (telomerase-
expressing) cells which were transfected with a control
siRNA directed against GFP (Figure 7A). Importantly,
telomeres were readily detectable in metaphase spreads
from each cell line. As previously reported, however, telo-
mere lengths were more heterogeneous in ALT cells
(16,19). Thus, the longest telomeres in U2OS cells yielded
signals of greater intensity, detected with Cy3-PNA, than
in HeLa cells. Furthermore, while nearly all telomeres
were detectable in HeLa cells, a striking number of telo-
meres in U2OS cells were not detectable with the
Cy3-PNA probe (Figure 7A).
As a measure of altered telomere function, we quanti-
ﬁed the percentage of signal-free telomeres in U2OS or
HeLa cells transfected with siRNAs directed against
GFP, FANCA or FANCD2 (Figure 7B). This assay has
been described previously (19,41). Depletion of FANCA
or FANCD2 with the appropriate siRNA was eﬀective in
both U2OS (ALT) (Figure 5A) and HeLa (telomerase-
expressing) cells (10). While 17.6 2.3% of the telomeres
were signal-free in U2OS cells transfected with the control
Figure 6. ATR is required for the colocalization of FANCD2 foci with
TRF1 foci in ALT cells following induction of DNA damage. (A)
U2OS ALT cells were transfected with a siRNA directed against
ATR or with a control siRNA directed against GFP. Immunoblots
for ATR and FANCD2 demonstrate ATR depletion and eﬀects on
FANCD2 monoubiquitination, respectively. Cells were either left
untreated or were exposed to HU for 24h. The ratio of monoubiqui-
tinated (-L) to non-ubiquitinated (-S) FANCD2 is indicated (L/S ratio).
An immunoblot for actin is shown as a loading control. (B)
Quantiﬁcation of the percentage of U2OS cells, transfected with
siRNAs directed against either GFP or ATR, which had ﬁve or more
FANCD2 foci following treatment with 0.5mM MMC for 24h. (C)
Quantiﬁcation of the percentage of U2OS cells, transfected with
siRNAs directed against either GFP or ATR, which had two or
more FANCD2 foci colocalized with telomeres detected with antibodies
to TRF1 following treatment with 0.5mM MMC for 24h. Each bar
represents the average of three counts of 150 or more cells  SD, and
diﬀerences in the behavior of FANCD2 foci were statistically diﬀerent
in cells transfected with siGFP and siATR (P<0.01) (B and C). (D)
ATR (red) and TRF1 (green) display a similar pattern of nuclear foci
in untreated GM847 ALT cells. Colocalization is demonstrated by
merged images (not shown). There is an apparent non-speciﬁc signal
detected by anti-ATR antibodies outside of the nucleus.
Nucleic Acids Research,2009, Vol.37, No. 6 1747Figure 7. Depletion of FANCA or FANCD2 results in an increased frequency of chromosome ends in ALT cells which are undetectable by in situ
hybridization with a probe for telomeric DNA. (A) Representative images for chromosomes assayed with a Cy3-labeled telomeric probe (PNA) (red)
or stained with DAPI (blue) in U2OS (ALT) or HeLa (telomerase-expressing) cells transfected with siRNAs against GFP (control). The telomeric
signal was more uniform in HeLa cells than in U2OS cells. Abnormally long telomeres and some telomere ends which were undetectable with Cy3-
PNA probe are indicated in the images for U2OS cells by ^ and
  symbols, respectively. (B and C) The percentage of signal-free chromosome ends,
quantiﬁed from images obtained from metaphase spreads of HeLa or U2OS cells (B) or GM847 cells (C). U2OS and HeLa cells were transfected
with siRNAs against GFP (control), FANCA or FANCD2. GM847 cells were transduced with shRNAs against FANCA or a scrambled control
(shScr). Cells were examined at 4 days following transfection or transduction. In each case, over 4000 telomeres were examined. For each value, the
average of four counts of ﬁve or more metaphases each is shown with the SD. Levels of signal-free telomeres in U2OS or GM847 ALT cells that
contained si/shRNAs against FANCA or FANCD2 were statistically diﬀerent (P<0.01) from cells transfected/transduced with control si/shRNAs.
(D) Histogram showing the distribution of telomere lengths in HeLa and U2OS cells, as determined by ﬂow FISH using Cy3-OO-(CCCTAA)3.
Results obtained in HeLa (black line) and U2OS (grey line) cells are overlayed for purposes of comparison. (E) Histograms of telomere lengths
(relative ﬂuorescence units) in U2OS ALT cells transfected with a control siRNA directed against GFP (left, dark blue line) or a siRNA directed
against FANCA (center, light blue line). An overlay of these results is shown at right. Diﬀerent settings for ﬂow cytometry were utilized
in ﬁgure parts D and E.
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mere ends was increased in U2OS cells in which either
FANCD2 or FANCA was depleted over a period of
only 4 days (45.5 1.7% and 39.7 5.3%, respectively)
(Figure 7B). Only a small percentage of telomeres were
signal-free in HeLa cells (less than 1.2% of total telomere
ends). Importantly, depletion of FANCA or FANCD2 in
HeLa cells had no eﬀect on the quantity of signal-free
ends, relative to cells transfected with the control siRNA
targeting GFP (Figure 7B).
To determine whether FANCA has a role in telomere
maintenance in multiple ALT cell lines, we also depleted
FANCA in GM847 cells and assayed for signal-free telo-
mere ends (Figure 7C). SiRNA oligonucleotides were
not eﬀective in GM847 cells (data not shown), so we
instead developed a lentiviral shRNA that targets
FANCA. Using this reagent, FANCA was eﬀectively
depleted and FANCD2 monoubiquitination was inhibited
(Supplementary Figure 2). While 35.3 1.9% of the telo-
meres were signal-free in GM847 cells transduced with the
control shRNA, the percentage of signal-free telomere
ends was increased in GM847 cells depleted of FANCA
over a period of only 4 days (56.5 4.9%) (Figure 7C).
We utilized ﬂow FISH for quantiﬁcation of telomere
length (Figure 7D and E). This approach measures the
combined length of all telomeres in the cell. Flow FISH
was capable of distinguishing a greater overall telomere
length in U2OS ALT cells [peak signal at 165 relative ﬂu-
orescence units (RFU), mean signal of 231 RFU] as com-
pared to HeLa telomerase-expressing cells [peak signal
at 96 RFU, mean signal of 127 RFU] (Figure 7D).
Importantly, depletion of FANCA had a negligible
eﬀect on overall telomere length in U2OS cells
(Figure 7E). These results suggest that depletion of
FANCA or FANCD2 results in destabilization of a
subset of telomeres in ALT cells, perhaps the shortest
telomeres, rather than a gradual attrition of all telomeres.
ALT cells maintain telomeres through homologous
recombination (15,16). Homologous recombination at
ALT telomeres is shown schematically in Figure 8A, and
a more detailed consideration of the molecular steps that
may be involved can be found elsewhere (42,43). Because
depletion of FANCA or FANCD2 results in the loss of
detectable telomeres in ALT cells (Figure 7), we sought to
determine whether FANCA and FANCD2 are required
for telomeric recombination in ALT cells. Sister chroma-
tid exchange at telomeres (T-SCE) can be measured by
CO-FISH (34). According to the protocol that we utilized
(shown schematically in Figure 8B), newly synthesized
strands were degraded and only the pre-existing strands
were detected by hybridization with a strand-speciﬁc telo-
mere probe [Cy3-(CCCTAA)3]. In the absence of a T-SCE
event, only a single signal at each end of the chromosome
was observed. In contrast, a T-SCE event resulted in a
signal that was split between the chromatids on a partic-
ular end of the chromosome (Figure 8B). Less frequently,
both ends of a chromosome underwent T-SCE and each
arm displayed a signal.
In the examples shown, T-SCE (indicated by a yellow
dot) was seen with a higher frequency in ALT U2OS cells
transfected with siGFP than in cells in which FANCD2
was depleted for 4 days (Figure 8C). It should be noted
that, in the examples shown, some chromosome ends
lacked telomeres which were detectable by CO-FISH.
The incidence of T-SCE per 100 chromosomes is quan-
tiﬁed in Figure 8D and E. Critically, transient depletion of
FANCA or FANCD2 in ALT U2OS cells resulted in an
equivalent decrease in total T-SCE events (25.0 3.8 and
23.7 3.3 per 100 chromosomes, respectively) relative to
controls transfected with siGFP (45.7 2.5 per 100 chro-
mosomes) (Figure 8D). Consistent with the previous
reports (17,18), T-SCE was much less frequent in HeLa,
which is not an ALT cell line. Furthermore, depletion of
FANCA or FANCD2 had no eﬀect on the frequency of
T-SCE in HeLa, as compared to populations transfected
with siGFP (Figure 8D). Transient depletion of FANCA
in GM847 ALT cells also resulted in a decrease in total
T-SCE events relative to controls transduced with a
control shRNA (40.6 5.2 and 18.9 2.1 per 100 chromo-
somes in cells containing shScr or shFANCA, respec-
tively) (Figure 8E).
Because depletion of FANCA or FANCD2 decreases
the frequency of detectable telomeres in U2OS cells
(Figure 7), we also determined the number of T-SCE
events relative to the number of chromosome ends with
detectable telomeres (Figure 8F). Depletion of either
FANCA or FANCD2 in U2OS ALT cells resulted in a
decrease in T-SCE at chromosome ends with telomeres
detectable by CO-FISH, whether a single signal or split
signal, as compared to U2OS cells transiently transfected
with siGFP (33.2 1.4, 20.2 2.1 and 21.3 2.1 per 100
signal positive ends in cells transfected with siGFP,
siFANCA and siFANCD2, respectively). Depletion of
FANCA in GM847 ALT cells also resulted in a decrease
in T-SCE at chromosome ends with telomeres detectable
by CO-FISH, as compared to GM847 cells transduced
with a control shRNA (18.2 2.3 and 11.8 0.8 per 100
signal positive ends in cells transduced with shScr and
shFANCA, respectively) (Figure 8G). Thus, we have
demonstrated a requirement for FANCA for T-SCE in
two diﬀerent ALT cell lines. Together, our results demon-
strate that FANCA and FANCD2 contribute to telomere
maintenance in ALT cells, at least in part, through a role
in homologous recombination.
DISCUSSION
The FA protein FANCD2 colocalizes with telomeres spe-
ciﬁcally in cell lines which maintain telomere length
through ALT. The colocalization of FANCD2 with telo-
meres in ALT cells requires two diﬀerent components of
the FA nuclear core complex, FANCA and FANCL.
Furthermore, depletion of FANCA, or FANCD2 itself,
increases the number of chromosome ends that lack
detectable telomere signals. Depletion of FANCA or
FANCD2 also results in a decrease in homologous recom-
bination (HR) between telomeres (T-SCE). Together, our
results suggest that monoubiquitinated FANCD2 is
involved in ALT telomere maintenance, at least in part,
through a role in T-SCE.
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ALT cells represents a novel function for monoubiquiti-
nated FANCD2 which is related to the maintenance of a
stable genome. While many DNA damage response pro-
teins localize to ALT telomeres (22–28,44–47), few, includ-
ing NBS1 and SMC5/6, have been directly implicated in
the maintenance of ALT telomeres (28,46). Thus, our
results, which demonstrate a role for the FA pathway,
are important for understanding ALT telomere mainte-
nance. In turn, ALT telomeres may provide an important
model for analysis of the function of FA proteins in HR.
FANCD2 foci colocalize withTRF1 foci in ALTcells
We have demonstrated the colocalization of FANCD2
with telomeres in ALT cells by independent means,
including colocalization with the telomere-binding
protein TRF1 and with telomeric DNA. We have not,
however, observed co-immunoprecipitation of FANCD2
with TRF1 or TRF2, either in the chromatin fraction
that contains monoubiquitinated FANCD2 (7) or
under conditions of increased FANCD2 monoubiquitina-
tion following the induction of DNA damage (data
not shown). FANCD2 may interact with other DNA
damage response proteins present at the ALT telomere
rather than interacting directly with TRF1 or TRF2.
Alternatively, monoubiquitinated FANCD2 might inter-
act with TRF1 or TRF2 only transiently in ALT cells,
perhaps in the context of HR between telomeres.
Figure 8. FANCA and FANCD2 are involved in telomere sister chro-
matid exchange (T-SCE) in ALT cells but not in telomerase-expressing
cells. (A) Schematic of homologous recombination at telomeres. In
normal cells, the 30 telomeric overhang loops back and invades
duplex DNA in the same telomere to form a T-loop that prevents
the telomere from being recognized as a DNA double-strand break.
In ALT cells, a 30 overhang of telomeres that is not protected in a
T-loop can initiate homologous recombination by invading another
telomere. Because telomeres are composed of 50-TTAGGG-30 repeats,
strand invasion can occur anywhere within the other telomere.
Replication can lengthen both strands of the invading telomere.
Recombination can be completed by resolution of the Holliday junc-
tion. (B) Schematic of the CO-FISH protocol utilized. Newly synthe-
sized strands were labeled with BrdU (dashed lines), and the strands
were nicked, following treatment with Hoecsht33258 and UV radiation,
and nicked strands digested with Exonuclease III. This left only the
parental DNA strands (solid lines). Telomeres were detected with a
strand-speciﬁc Cy3-labeled probe (PNA) by FISH (indicated by red
spot). This diagram also shows a signal split between sister chromatids,
indicating T-SCE. (C) Representative images of CO-FISH for U2OS
cells transfected with siRNAs against GFP (control) or FANCD2.
Telomeres remaining after digestion of newly replicated strands were
detected with a Cy3-labeled telomeric probe (PNA) (red) and the entire
chromosome was stained with DAPI (blue), as shown in merged
images. Representative T-SCE events are indicated by yellow dots.
More T-SCE events were observed in cells treated with siGFP than
in those treated with siFANCD2. Some chromosome ends lacked
detectable telomeres, and not all T-SCE events are visible in the
merged images shown. (D and E) The number of T-SCE events per
100 chromosomes is shown for U2OS (ALT) or HeLa (telomerase-
expressing) cells (D), or GM847 cells (E). (F and G) The number of
T-SCE events per 100 chromosome ends detectable with the telomere
probe is shown for U2OS or HeLa cells (F), or GM847 cells (G). U2OS
and HeLa cells were transiently transfected with siRNAs that targeted
GFP, FANCA or FANCD2, and GM847 cells were transduced with
shRNAs directed against FANCA or a scrambled control (shScr)
(D–G). Cells were analyzed 4 days after transfection or transduction.
Values represent the average of four groups of nine metaphases each
 SD (D–G). A minimum of 2000 chromosomes were examined for
each sample. Levels of T-SCE in U2OS or GM847 ALT cells depleted
of FANCA or FANCD2 were statistically diﬀerent (P<0.01) from
levels in cells transfected or transduced with control shRNAs.
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TRF1 inALT cells
Our results demonstrate that the FA nuclear core complex
and ATR are required both for the distribution of
FANCD2 to ALT telomeres and to sites of DNA
damage induced by various genotoxic agents (3,7,10). In
fact, FANCD2 may localize to ALT telomeres as part of a
specialized DNA damage response. This is supported by
our ﬁnding that treatment with MMC induces an
increased colocalization of FANCD2 with ALT telomeres
(Figure 5B). Furthermore, ALT cells contain telomeres
with DNA termini recognized as DNA double-strand
breaks (47).
ATR colocalizes with telomeres in ALT cells
(Figure 6D), and thus may directly regulate FANCD2
monoubiquitination at this site. We have not, however,
determined whether ATR is required for ALT telomere
maintenance.
FANCA and FANCD2are requiredfor telomere
maintenance inALT cells
We have demonstrated, by an increased frequency of chro-
mosome ends lacking detectable telomeres (Figure 7), that
depletion of either FANCA or FANCD2 results in an
alteration of telomeres in ALT cells. This has been exam-
ined by a widely utilized method of FISH with a probe
that recognizes TTAGGG telomeric repeats (41,48,49).
Importantly, transient depletion of FANCA or
FANCD2 over a period of 4 days results in a similar
increase in the frequency of signal-free ends in U2OS
ALT cells. Together, our results suggest that FANCA
and FANCD2 may function in a pathway, leading to
FANCD2 monoubiquitination, that contributes to ALT
telomere maintenance.
In addition to gradual telomere attrition, ALT cells dis-
play rapid decreases or increases of telomere length of
multiple kilobases (50). We propose that a deﬁciency for
FANCD2 or its monoubiquitination may lead to rapid
telomere shortening in ALT cells due, at least in part, to
a demonstrated defect in the T-SCE that is required for
telomere lengthening. Changes in overall telomere length
are not detected in ALT cells by ﬂow FISH following
transient depletion of FANCA (Figure 7E). This may
indicate that monoubiquitinated FANCD2 has a role in
maintaining only the shortest telomeres in ALT cells.
Monoubiquitinated FANCD2 might also normally act
to stabilize or cap linear DNA present at APBs (51). In
this context, it is interesting that the telomeric protein,
POT1b, is involved both in stabilizing telomeres and in
regulating T-SCE (52).
While lymphoblasts from FA patients have shorter telo-
meres relative to age-matched controls (53–55), a previous
study using mouse and human cells deﬁcient for FA
nuclear core complex proteins demonstrated no direct
role for the FA pathway in telomere maintenance in
non-ALT cells (56). This is in accord with our ﬁnding
that FANCD2 does not colocalize with telomeres in
non-ALT cells and therefore is not expected to have a
role in telomere maintenance in such cells.
Functionsof FAproteins inhomologous recombination
We demonstrate that deﬁciency for FANCA or FANCD2
results in a decrease in T-SCE, which is a form of homol-
ogous recombination required for ALT telomere mainte-
nance (15,16). It should be noted that not all proteins that
have an integral role in homologous recombination are
required for T-SCE or for ALT telomere maintenance.
An example of this is RAD54 (17). Thus, FA proteins
may be involved in a speciﬁc form of HR that is utilized
to maintain ALT telomeres.
Deﬁciency for FA proteins, such as FANCA, FANCG
and FANCD2, is associated with a modest defect in DNA
double-strand break-induced HR (57–59). Based upon
such results, it has been suggested that FA proteins,
other than BRCA2/FANCD1 and its partner, PALB2/
FANCN, have a regulatory role in HR, rather than a
direct mechanistic function in this type of repair (60).
The assays of DNA double-strand break-induced HR
described earlier utilized a reporter introduced into
DNA (57–59). In contrast, the function of FA proteins
in T-SCE represents homologous recombination in a
physiological context. As such, ALT telomeres may rep-
resent an important system for understanding the function
of FA proteins in DNA repair.
Rolesof DNA damage response proteins at APBs
Incorporation of bromodeoxyuridine at APBs during late
S phase/G2 (21–23) could be related either to replication
of telomeric DNA or homologous recombination at telo-
meres. We suggest that monoubiquitinated FANCD2 has
a function in the maintenance of ALT telomeres that is
related to DNA repair rather than DNA replication. First,
we have demonstrated a function for FANCA and
FANCD2 in T-SCE. Second, FA proteins have been
implicated in DNA repair in non-ALT cells (57–59), and
FANCD2 is not a constitutive component of the replica-
tion machinery (61). Third, neither FANCD2 nor its
monoubiquitination signiﬁcantly inﬂuences the rate of
bulk DNA replication (9). Finally, similar to FANCD2,
other DNA repair-related proteins, such as NBS1 and
SMC5/6, have a role in T-SCE and colocalize with
APBs during late S phase/G2 (22,28).
How T-SCE acts to maintain ALT telomeres is not well
understood. The DNA repair proteins WRN and Ku70,
and the telomeric proteins Pot1a and b, suppress sister
chromatid exchange at telomeres (T-SCE) (48,52,62,63).
In contrast, the FA pathway, along with SMC5/6 (28),
appears to be required for the T-SCE that drives telomere
maintenance in ALT cells (15,16). The functional relation-
ship of SMC5/6 to FA proteins in T-SCE, if any, is
unknown at present.
Interestingly, our results suggest that two diﬀerent ubi-
quitin-related or ubiquitin-like protein modiﬁcations are
involved in ALT telomere maintenance. It has been
reported that sumoylation of the telomere-binding pro-
teins TRF1 and TRF2 is dependent upon SMC5/6.
Further, SMC5/6 are required for the formation of
APBs and for T-SCE in ALT cells (28). Our ﬁndings
suggest that monoubiquitination of FANCD2 is also
Nucleic Acids Research,2009, Vol.37, No. 6 1751required for colocalization of this protein with APBs and
for T-SCE in ALT cells.
Consequencesof thetelomeric localization of FANCD2 in
ALTcells for cancer formationand fortherapy
Given our ﬁnding that FANCA and FANCD2 are specif-
ically involved in the maintenance of telomeres in ALT
cells, it is expected that tumors in FA patients likely
express telomerase, rather than relying on the ALT path-
way for telomere stabilization. Indeed, the most prevalent
malignancies in FA patients are AML and squamous car-
cinoma of the head and neck (1). These cancers utilize
ALT with a low frequency (14,64).
Because of a defect in the cellular response to DNA
damage, FA patients are potentially hypersensitive to
radiotherapy or chemotherapy (1,65). If tumors in FA
patients uniquely develop through reactivation of telome-
rase, perhaps inhibition of telomerase (66) will be a more
eﬀective therapeutic strategy to which FA patients are not
hypersensitive.
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